¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug Resistance, Multiple, Viral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • drug dependence
    ¾à¹°ÀÇÁ¸
  • drug dispensing
    ¾à¹°Á¶Á¦
  • drug eruption
    ¾à¹°¹ßÁø, ¾àÁø
  • drug idiosyncrasy
    ¾à¹°Æ¯ÀÌüÁú
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë
  • drug interference
    ¾à¹°°£¼·
  • drug intoxication
    ¾à¹°Áßµ¶
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • drug of choice
    ÀÏÂ÷¼±Åþà
  • drug overdose
    1. ¾à¹°°ú·®Åõ¿© 2. ¾à¹°°ú·®
  • drug plant
    ¾àÃÊ
  • drug potentiation
    ¾à¹°°­È­ÀÛ¿ë, ¾à¹°»ó½ÂÀÛ¿ë
  • drug psychosis
    ¾à¹°Á¤½Åº´
  • drug rash
    ¾à¹°¹ßÁø, ¾àÁø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
  • drug addiction
    ¾à¹°Áßµ¶
  • drug adjuvant
    ÀǾàǰ÷°¡¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
  • drug-induced hemolytic anemia
    ¾à¹°À¯¹ß¿ëÇ÷ºóÇ÷
  • new drug application
    ½Å¾àÇã°¡½Åû
  • drug resistant bacterium
    ¾àÁ¦³»¼º±Õ
  • chemotherapeutic drug monitoring
    È­Çпä¹ý¾àÁ¦°¨½Ã
  • cognitive-acting drug
    ÀÎÁö±â´ÉȰ¼ºÁ¦
  • common drug
    º¸Åë¾à
  • crude drug
    Á¶¾à
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • resistance to infections
    °¨¿°ÀúÇ×¼º(Êïæøî½ù÷àõ).
  • resistance to poison
    ³»µ¶¼º(Ò±Ô¸àõ).
  • resistance transfer factor
    ³»¼ºÀü´ÞÀÎÀÚ(Ò±àõîîÓ¹ì×í­).
  • resistance vessel
    ÀúÇ×Ç÷°ü(î½ù÷úìη).
  • resistance, cross
    ±³Â÷³»¼º
  • resistance, heterogenous
    ºñ±ÕÀϳ»¼º¹ÝÀÀ
  • resistance, natural
    ÀÚ¿¬³»¼º, º»Å¼º³»¼º
  • resistance, one-way cross
    ±³Â÷ÀϹ泻¼º
  • respiratory resistance
    È£ÈíÀúÇ×(¡­î½ù÷).
  • sense of resistance
    ÀúÇ×°¨°¢(î½ù÷ÊïÊÆ).
  • shock resistance
    ¼ï³»¼º(¡­Ò±àõ), Ãæ°ÝÀúÇ×¼º(õú̪î½ù÷àõ).
  • shock resistance
    ¼ï³»¼º(¡­Ò±àõ), Ãæ°ÝÀúÇ×¼º(õú̪î½ù÷àõ)
  • specific resistance
    ºñÀúÇ×(Ýïî½ù÷).
  • tear resistance
    Àο­ÀúÇ×(ìÚæñî½ù÷).
  • total peripheral resistance
    Àü<ÃÑ>¸»ÃÊÀúÇ×(îï<õÅ>ØÇôþî½ù÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
VHD valvular heart disease; viral hematodepressive disease
VHF very high frequency; viral hemorrhagic fever; visual half-field
Vir virus, viral
VM vasomotor; ventralis medialus; ventromedial; ventricular mass; ventriculometry; vestibular membrane;...
V-ONC viral oncogene
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
CDER Center for Drug Evaluation and Research
CIDR Controlled Internal Drug Release
DARP Drug Abuse Reporting Program
DATOS Drug Abuse Treatment Outcome Study
DAWN Drug Abuse Warning Network
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • drug induced disorder
    ¾à¹° À¯¹ß¼º Áúȯ
  • drug industry
    ¾à¹° Á¦¾à °ø¾÷
  • drug interference
    ¾à¹° °£¼·
  • drug metabolism
    ¾à¹° ´ë»ç
  • drug misuse
    ¾à¹° ¿À¿ë
    ¾à¹°À» ºÎÀûÇÕÇÏ°Ô »ç¿ëÇÏ¿© »ý±â´Â Áõ»óÀ¸·Î ¾à¹° ³²¿ë
  • drug of choice
    ¼±Åà ¾àÁ¦, Ưȿ ¾à
  • drug overload
    ¾à¹° °ú·® º¹¿ë
  • drug potentialization
    ¾à¹° »ó½Â, ¾à¹° »ó½Â ÀÛ¿ë
  • drug prophylaxis
    ¾àÁ¦ ¿¹¹æ
  • drug rash
    ¾à¹°¼º ¹ßÁø, ¾àÁø
  • drug receptor
    ¾à¹° ¼ö¿ëü
  • drug shock
    ¾à¹° Ãæ°Ý
  • drug side effect
    ºÎÀÛ¿ë
  • drug therapy
    ¾à¹° º¹¿ë
  • drug treatment
    ¾à¹° ¿ä¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
viral core proteins Proteins found mainly in icosahedral DNA and RNA viruses. They consist of proteins directly associated with the nucleic acid inside the nucleocapsid.
(12 Dec 1998)
viral cystitis Bladder inflammation due to a viral infection.
(05 Mar 2000)
viral dysentery Profuse watery diarrhoea due to, or thought to be due to, infection by a virus.
(05 Mar 2000)
viral encephalomyelitis An encephalomyelitis due to a neurotropic virus.
(05 Mar 2000)
viral envelope The outer structure that encloses the nucleocapsids of some viruses; may contain host material.
(05 Mar 2000)
viral envelope proteins Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
(12 Dec 1998)
viral fusion proteins Proteins, usually glycoproteins, found in the viral envelopes of a variety of viruses. They promote cell membrane fusion and thereby may function in the uptake of the virus by cells.
(12 Dec 1998)
viral gastroenteritis <pathology> An inflammatory condition of the intestines that results from an infection with a virus. Rotavirus is a common cause. Abdominal pain, diarrhoea, nausea and vomiting are common symptoms.
(27 Sep 1997)
viral haemagglutination The nonimmune agglutination of suspended red blood cells by certain of a wide range of otherwise unrelated viruses, usually by the virion itself but in some instances by products of viral growth, the species of erythrocyte agglutinated differing with the different viruses.
See: haemagglutination inhibition.
(05 Mar 2000)
viral haemorrhagic fever An epidemic viral illness seen in southern Sudan and Zaire, caused by the Ebola virus. The illness is characterised by fever, malaise, muscle aches, respiratory symptoms, diarrhoea, vomiting, epistaxis, haemoptysis, haematemesis, rash, tremors and subconjunctival haemorrhages. Transmitted by close bodily contact with infected individuals (blood, faeces and body fluids). Incubation is-21 days with initial symptoms of fever and headache. There is no specific treatment and death can occur within 10 days.
(27 Sep 1997)
viral haemorrhagic fever virus <virology> An epidemic viral illness seen in southern Sudan and Zaire, caused by the Ebola virus. The illness is characterised by fever, malaise, muscle aches, respiratory symptoms, diarrhoea, vomiting, epistaxis, haemoptysis, haematemesis, rash, tremors and subconjunctival haemorrhages. Transmitted by close bodily contact with infected individuals (blood, faeces and body fluids). Incubation is-21 days with initial symptoms of fever and headache. There is no specific treatment and death can occur within 10 days.
(27 Sep 1997)
viral hepatitis Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver.
(12 Dec 1998)
viral hepatitis type A A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
viral hepatitis type B A virus disease with a long incubation period (usually 50 to 160 days), caused by hepatitis B virus, a DNA virus and member of the family Hepadnoviridae, usually transmitted by injection of infected blood or blood derivatives or by use of contaminated needles, lancets, or other instruments; clinically and pathologically similar to viral hepatitis type A, but there is no cross-protective immunity; HBsAg is found in the serum and the hepatitis delta virus occurs in some patients.
Synonym: hepatitis B, serum hepatitis, transfusion hepatitis, virus B hepatitis.
(05 Mar 2000)
viral hepatitis type C Principal cause of non-A, non-B posttransfusion hepatitis caused by an RNA virus that may be related to Flaviviridae family.
Synonym: hepatitis C, virus C hepatitis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á